A Case of Cutaneous Squamous Cell Carcinoma Treated with Neoadjuvant Cemiplimab
Main Article Content
Keywords
immunotherapy, cemiplimab, squamous cell carcinoma, cancer
Abstract
We present a case describing the successful treatment of a 68-year-old male with high-risk cutaneous squamous cell carcinoma (cSCC) using neoadjuvant cemiplimab. The patient presented with a rapidly growing papule on the left hand, which was initially treated with wide local excision and subsequently developed axillary lymphadenopathy. After radiation therapy led to complications, the patient received four cycles of cemiplimab, resulting in significant tumor necrosis and minimal residual disease. This case underscores the potential of cemiplimab as a neoadjuvant therapy for cSCC, offering an effective treatment with fewer adverse effects compared to traditional therapies. The report highlights the importance of a multidisciplinary approach in optimizing outcomes for patients with advanced cSCC.
References
2. NCCN . Squamous cell skin cancer guidelines (Version 1.2024). Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
3. Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L. S., Rabinowits, G., Thai, A. A., Dunn, L. A., Hughes, B. G. M., Khushalani, N. I., Modi, B., Schadendorf, D., Gao, B., Seebach, F., Li, S., … Fury, M. G. (2018). PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. The New England journal of medicine, 379(4), 341–351. https://doi.org/10.1056/NEJMoa1805131
4. Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F., Su, Y. B., Swiecicki, P. L., Atlas, J., Geiger, J. L., Hauschild, A., Choe, J. H., Hughes, B. G. M., Schadendorf, D., Patel, V. A., Homsi, J., Taube, J. M., Lim, A. M., Ferrarotto, R., … Rischin, D. (2023). Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet. Oncology, 24(11), 1196–1205. https://doi.org/10.1016/S1470-2045(23)00459-X
5. Walsh, L., Gillham, C., Dunne, M., Fraser, I., Hollywood, D., Armstrong, J., & Thirion, P. (2011). Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 98(1), 38–41. https://doi.org/10.1016/j.radonc.2010.11.009
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.